The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy.
C. Suzuki
No relevant relationships to disclose
L. Blomqvist
No relevant relationships to disclose
A. Sundin
No relevant relationships to disclose
P. Bystrom
No relevant relationships to disclose
A. Berglund
No relevant relationships to disclose
H. Jacobsson
No relevant relationships to disclose
P. Nygren
No relevant relationships to disclose
B. Glimelius
Research Funding - Merck; Pfizer